The immunologic basis for the treatment of psoriasis with new biologic agents

Journal of the American Academy of Dermatology

Volumn 46, Issue 1, 2002, Pages 1-26

  Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYCLOSPORIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EFALIZUMAB; EPIDERMAL GROWTH FACTOR; HYBRID PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; KERATINOCYTE GROWTH FACTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; LYMPHOKINE; METHOTREXATE; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PSORALEN; RETINOID; SIPLIZUMAB; SOMATOMEDIN C; T LYMPHOCYTE RECEPTOR; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ANTIGEN PRESENTING CELL; BIOLOGICAL THERAPY; BLOOD VESSEL; CELLULAR IMMUNITY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EPIDERMIS CELL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LANGERHANS CELL; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; ULTRAVIOLET B RADIATION;

EID: 0036145337     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.120568     Document Type: Article

References (143)

1. Current consensus and update on psoriasis therapy: A perspective from the U.S.
2. Psoriasis: Current perspectives with an emphasis on treatment
3. An approach to the treatment of moderate to severe psoriasis with rotational therapy
4. Systemic sequential therapy of psoriasis: A new paradigm for improved therapeutic results
5. Successful in vivo blockade of CD2S (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-TAC antibody to patients with psoriasis
6. Changes in keratinocyte maturation during wound healing
7. Immunological aspects of psoriasis
8. Pathogenic interations of keratinocytes and T lymphocytes in psoriasis
9. The dermal inflammatory reaction in intitial psoriatic lesions
10. Characterization of mononuclear cell infiltrates in psoriatic lesions
11. Identification of subpopulation of mononuclear cells in psoriatic lesions
12. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies
13. Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques
14. Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased skin
15. Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis
16. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: Blood and skin comparisons by flow cytometry
17. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients
18. CDB+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes
19. Psoriasis: A disease of abnormal keratinocyte proliferation induced by T lymphocytes
20. Psoriasis: A T-cell mediated autoimmune disease induced by streptococcal superantigens?
21. The action of topical steroids, dithranol, and PUVA on T lymphocytes and dendritic cells in psoriasis
22. Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: The effects of PUVA treatment
23. Cyclosporine improves psoriasis in a double-blind study
24. The pathomechanisms of psoriasis: The skin immune system and cyclosporin
25. Cycloporine in psoriasis treatment: Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor alpha/epidermal growth factor receptor pathways
26. A potential role for superantigens in the pathogenesis of psoriasis
27. Psoriasiform dermatitis of AIDS
28. Psoriasis induced by interferon-alpha
29. Psoriasis induced at the injection site of recombinant interferon gamma: Results of immunohistologic investigations
30. Systemic tacrolimus (Fk 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study
31. Response of psoriasis to a lymphocyte-selective toxin (DAB3891L-2) suggests a primary immune, but not keratinocyte, pathogenic basis
32. Dermal injection of immunocytes induces psoriasis
33. The immunologic and genetic basis of psoriasis
34. 312-Nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions
35. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in normal and malignant T-lymphocytes
36. Methotrexate therapy of psoriasis: Differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate
37. Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: Evidence for selective effects on activated T lymphocytes
38. Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infilitration in psoriatic plaques by topical calcitriol
39. Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selection on T cells during the virgin to memory cell transition
40. Lymphocyte homing and homeostasis
41. L-selectin-mediated leukocyte adhesion in vivo: Microvillous distribution determines tethering efficiency, but not rolling velocity
42. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3beta receptor CCR7
43. Molecular mechanisms of lymphocyte homing to peripheral lymph nodes
44. Dendritic cells and the control of immunity
45. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA41g) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells
46. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors
47. Complexity in the major histocompatibility complex
48. Lymphocyte activation in health and disease
49. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines
50. Regulation of T-cell lymphokine gene transcription by the accessory molecule CD28
51. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
52. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice
53. T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: A ligand for CD28
54. The role of CD40 and its ligand in the regulation of the immune response
55. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate
56. Generation of monocyte-derived dendritic cells from precursors in rhesus macaque blood
57. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
58. Accessory signaling by CD40 for T cell activation: Induction of Th1 and Th2 cytokines and synergy with interleukin-12 for interferon-gamma production
59. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
60. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
61. The expanding universe of T-cell subsets: Th1, Th2 and more
62. Th1-Th2 paradigm: Insights from leprosy
63. Mechanism involved in the systemic suppression of antigen-presenting cell function by UV irradiation: Keratinocyte-derived IL-10 modulates antigen-presenting cell function of splenic adherent cells
64. Interleukin-4 (IL-4) induces down-modulation and shedding of the p55 tumour necrosis factor receptor and inhibits TNF alpha's effect on rheumatoid synovial fibroblasts
65. T cells involved in psoriasis vulgaris belong to the Th1 subset
66. Low dose ultraviolet B-irradiated Langerhans cells preferentially activate CD4+ cells of the T helper 2 subset
67. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function
68. Expression of interleukin-12 is increased in psoriatic skin
69. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions
70. ELAM-1 is an adhesion molecule for skin-homing T cells
71. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells
72. Inflammatory skin diseases, T cells, and immune surveillance
73. Effect of in vivo interleukin-1 on adhesion molecule expression in normal human skin
74. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells
75. Recent advances in chemokines and chemokine receptors
76. Chemokines: A new classification system and their role in immunity
77. Cutting edge: The orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC)
78. Up-regulation of macrophage inflammatory protein-3a/CCL20 and CC chemokine receptor 6 in psoriasis
79. Chemokines as regulators of T cell differentiation
80. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions
81. Upregulation of RANTES in psoriatic keratinocytes: A possible pathogenic mechanism for psoriasis
82. RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol)
83. Potential role of the chemokine receptors CXCR3, CCR4, and the integrin αEβ7 in the pathogenesis of psoriasis vulgaris
84. Significance and pathogenesis of basal keratinocyte herniations in psoriasis
85. Differential expression of GRO-α and IL-8 mRNA in psoriasis: A model for neutrophil migration and accumulation in vivo
86. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells
87. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice
88. Models of T cell anergy: Is there a common molecular mechanism?
89. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides
90. T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides
91. Persistence of T-cell clones in psoriatic lesions
92. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro
93. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees
94. HuM291 (Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor
95. Anti-CD2 episilon F(ab') 2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens
96. Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment
97. A humanized non-FCR-binding anti-CD3 versus-host disease
98. Anti-CD4 monoclonal antibody therapy in severe psoriasis
99. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4
100. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: Results of a pilot, multicenter, multiple-dose, placebo-controlled study
101. T cell costimulatory pathways: Promising novel targets for immunosuppression and tolerance induction
102. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation
103. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2
104. Immunological functions of non-professional antigen-presenting cells: New insights from studies of T-cell interactions with keratinocytes
105. Treatment of murine lupus with CTLA41g
106. In vivo blockade of CD28/CTLA4:B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice
107. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis
108. Tolerance induction by soluble CTLA4 in a mouse skin transplant model
109. CTLA41g-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
110. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression
111. Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis
112. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10: Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression
113. Interleukin 10 treatment of psoriasis: Clinical results of a phase 2 trial
114. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
115. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection
116. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells
117. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
118. Regulation of the human interleukin-2/interleukin-2 receptor system: A role for immunosuppression
119. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
120. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody
121. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies
122. Biology of the interleukin-2 receptor
123. Administration of DAB3891L-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial
124. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach
125. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation
126. Interleukin 4-induced immune deviation as therapy for psoriasis
127. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression in profiling
128. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
129. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
130. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: Analysis of the mechanism of action predicts utility in other diseases
131. Treatment with anti-tumor necrosis factor a (TNF-a) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
132. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomized trial
133. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial
134. Treatment of psoriatic arthritis with antitumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate
135. Clinical trials of a fully human anti-iL8 antibody for the treatment of psoriasis
136. Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treament with multiple doses of efalizumab, an anti-CD11a antibody
137. Therapeutic CD11a ligation tranmodulates surface expression of β1 and β2 integrins on T-lymphocytes
138. T lymphocytes and monocytes bind to keratinocytes in frozen sections of biopsy specimens of normal skin treated with gamma interferon
139. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: Cell surface antigens associated with CTL-target interactions
140. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody
141. Anti-E-selection in the treatment of psoriasis
142. Antisense intercellular adhesion molecule-1 (ICAM-1) oligodeoxyribonucleotide delivered during organ preservation inhibits posttransplant ICAM-1 expression and reduces primary lung isograft failure
143. Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity